Company

About

Crux Biolabs

Crux Biolabs

885 Mountain Hwy, Bayswater, Victoria 3153, AU

Crux Biolabs is an Australian bioanalytical laboratory specialising in PBMC processing, pharmacodynamics (biomarker, flow cytometry, ELISpot and ADA) and pharmacokinetics (large and small molecule) for clinical research. Our expert scientists can customise and validate a wide range of biomarker and cell assays in our ISO 17025 accredited lab in Melbourne, Australia. We also offer PBMC processing in Sydney with our dedicated satellite laboratory. We understand that each study is unique. That's why we take pride in becoming an extension of your team to deliver the best outcome for your studies. Crux Biolabs - where science leads.

Gelomics

Gelomics

Kelvin Grove, Queensland

Gelomics is revolutionizing drug development by enabling the growth of human tissue models in vitro, providing an ethical, cost-effective, and predictive alternative to animal testing. Our mission is to accelerate therapeutic breakthroughs, ensuring faster, safer, and more humane medical advancements.

Inventia

Inventia

Alexandria, Australia

Inventia Life Science is making advanced cell models easy for high impact discovery. The company's strong foundation of fundamental research has led to the development of proprietary solutions to generate high-quality advanced cell models that are reproducible and highly consistent. Built by scientists for scientists, our intuitive solutions integrate seamlessly with existing workflows, whereas our wide range of biofunctional synthetic matrices and application-driven models make your desired assays possible.

NeuClone

NeuClone

Sydney, Australia

NeuClone is a clinical stage biopharmaceutical company exclusively developing and commercialising high quality biosimilar products. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at the scale and price to meet demand in both new and established markets globally. NeuClone is differentiated by our deep and unmatched pipeline, as well as our Right From the Start® approach where we continually confirm biosimilarity at the earliest stages and throughout development.